Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 16 of 794 for:    LENALIDOMIDE AND cells

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00807599
Recruitment Status : Completed
First Posted : December 12, 2008
Results First Posted : March 15, 2019
Last Update Posted : March 15, 2019
Sponsor:
Collaborators:
Tufts Medical Center
Lahey Clinic
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Study Type Interventional
Study Design Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition Multiple Myeloma
Interventions Procedure: Stem cell transplant x 1 or x 2
Drug: lenalidomide and dexamethasone
Enrollment 67
Recruitment Details  
Pre-assignment Details  
Arm/Group Title Continue Lenalidomide and Dexamethasone Stem Cell Transplant x 1 or x 2 Not Evaluable
Hide Arm/Group Description

All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :

stem cell transplant right after collection

  • continue lenalidomide and dexamethasone
  • saving stem cell transplant for a later time.

lenalidomide and dexamethasone: Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.

All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :

  • stem cell transplant right after collection
  • continue lenalidomide and dexamethasone, saving stem cell transplant for a later time.

Stem cell transplant x 1 or x 2: After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.

On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L.

Participants were not randomized and are not evaluable
Period Title: Overall Study
Started 26 24 17
Completed 26 24 0
Not Completed 0 0 17
Reason Not Completed
Not treated on protocol study             0             0             2
Adverse Event             0             0             5
Inadequate response to induction             0             0             9
Withdrawal by Subject             0             0             1
Arm/Group Title Continue Lenalidomide and Dexamethasone Stem Cell Transplant x 1 or x 2 Total
Hide Arm/Group Description

All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :

stem cell transplant right after collection

  • continue lenalidomide and dexamethasone
  • saving stem cell transplant for a later time.

lenalidomide and dexamethasone: Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.

All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :

  • stem cell transplant right after collection
  • continue lenalidomide and dexamethasone, saving stem cell transplant for a later time.

Stem cell transplant x 1 or x 2: After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.

On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L.

Total of all reporting groups
Overall Number of Baseline Participants 26 24 50
Hide Baseline Analysis Population Description
[Not Specified]
Age, Continuous  
Mean (Full Range)
Unit of measure:  Years
Number Analyzed 26 participants 24 participants 50 participants
61.3
(47 to 71)
60.5
(50 to 69)
60.96
(47 to 71)
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 26 participants 24 participants 50 participants
Female
13
  50.0%
8
  33.3%
21
  42.0%
Male
13
  50.0%
16
  66.7%
29
  58.0%
Race (NIH/OMB)  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 26 participants 24 participants 50 participants
American Indian or Alaska Native
0
   0.0%
0
   0.0%
0
   0.0%
Asian
0
   0.0%
1
   4.2%
1
   2.0%
Native Hawaiian or Other Pacific Islander
0
   0.0%
0
   0.0%
0
   0.0%
Black or African American
6
  23.1%
3
  12.5%
9
  18.0%
White
19
  73.1%
20
  83.3%
39
  78.0%
More than one race
0
   0.0%
0
   0.0%
0
   0.0%
Unknown or Not Reported
1
   3.8%
0
   0.0%
1
   2.0%
Region of Enrollment  
Measure Type: Count of Participants
Unit of measure:  Participants
United States Number Analyzed 26 participants 24 participants 50 participants
26
 100.0%
24
 100.0%
50
 100.0%
1.Primary Outcome
Title Progression Free Survival (PFS) Rate at 2 Years After Enrollment in Untreated Patients With Multiple Myeloma.
Hide Description [Not Specified]
Time Frame 2 years
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Continue Lenalidomide and Dexamethasone Stem Cell Transplant x 1 or x 2
Hide Arm/Group Description:

All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :

stem cell transplant right after collection

  • continue lenalidomide and dexamethasone
  • saving stem cell transplant for a later time.

lenalidomide and dexamethasone: Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.

All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :

  • stem cell transplant right after collection
  • continue lenalidomide and dexamethasone, saving stem cell transplant for a later time.

Stem cell transplant x 1 or x 2: After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.

On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L.

Overall Number of Participants Analyzed 26 24
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
84.6
(70.7 to 98.5)
83.3
(68.4 to 98.2)
2.Secondary Outcome
Title Number of Participants With VGPR + CR Rate
Hide Description

VGPR/Very Good Partial Response + CR/Complete Response (>/= VGPR) for each study arm

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Time Frame 2 years
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Continue Lenalidomide and Dexamethasone Stem Cell Transplant x 1 or x 2
Hide Arm/Group Description:

All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :

stem cell transplant right after collection

  • continue lenalidomide and dexamethasone
  • saving stem cell transplant for a later time.

lenalidomide and dexamethasone: Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.

All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :

  • stem cell transplant right after collection
  • continue lenalidomide and dexamethasone, saving stem cell transplant for a later time.

Stem cell transplant x 1 or x 2: After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.

On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L.

Overall Number of Participants Analyzed 26 24
Measure Type: Count of Participants
Unit of Measure: Participants
>/= VGPR
18
  69.2%
21
  87.5%
<VGPR
8
  30.8%
3
  12.5%
3.Secondary Outcome
Title Overall Response Rates
Hide Description Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Time Frame 2 years
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Continue Lenalidomide and Dexamethasone Stem Cell Transplant x 1 or x 2
Hide Arm/Group Description:

All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :

stem cell transplant right after collection

  • continue lenalidomide and dexamethasone
  • saving stem cell transplant for a later time.

lenalidomide and dexamethasone: Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.

All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :

  • stem cell transplant right after collection
  • continue lenalidomide and dexamethasone, saving stem cell transplant for a later time.

Stem cell transplant x 1 or x 2: After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.

On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L.

Overall Number of Participants Analyzed 26 24
Measure Type: Count of Participants
Unit of Measure: Participants
Stringent Complete Response
12
  46.2%
12
  50.0%
Very Good Partial Response
6
  23.1%
7
  29.2%
Partial Response
8
  30.8%
3
  12.5%
Complete Response
0
   0.0%
2
   8.3%
4.Secondary Outcome
Title Overall Survival
Hide Description [Not Specified]
Time Frame up to 4 years
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Continue Lenalidomide and Dexamethasone Stem Cell Transplant x 1 or x 2
Hide Arm/Group Description:

All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :

stem cell transplant right after collection

  • continue lenalidomide and dexamethasone
  • saving stem cell transplant for a later time.

lenalidomide and dexamethasone: Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.

All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :

  • stem cell transplant right after collection
  • continue lenalidomide and dexamethasone, saving stem cell transplant for a later time.

Stem cell transplant x 1 or x 2: After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.

On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L.

Overall Number of Participants Analyzed 26 24
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants alive
95.7
(87.3 to 99.9)
90.6
(78.2 to 99.9)
Time Frame Up to 4 years
Adverse Event Reporting Description [Not Specified]
 
Arm/Group Title Continue Lenalidomide and Dexamethasone Stem Cell Transplant x 1 or x 2
Hide Arm/Group Description

All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :

stem cell transplant right after collection

  • continue lenalidomide and dexamethasone
  • saving stem cell transplant for a later time.

lenalidomide and dexamethasone: Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.

All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :

  • stem cell transplant right after collection
  • continue lenalidomide and dexamethasone, saving stem cell transplant for a later time.

Stem cell transplant x 1 or x 2: After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.

On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L.

All-Cause Mortality
Continue Lenalidomide and Dexamethasone Stem Cell Transplant x 1 or x 2
Affected / at Risk (%) Affected / at Risk (%)
Total   3/26 (11.54%)   5/24 (20.83%) 
Show Serious Adverse Events Hide Serious Adverse Events
Continue Lenalidomide and Dexamethasone Stem Cell Transplant x 1 or x 2
Affected / at Risk (%) Affected / at Risk (%)
Total   17/26 (65.38%)   18/24 (75.00%) 
Blood and lymphatic system disorders     
Febrile neutropenia   4/26 (15.38%)  4/24 (16.67%) 
Hemoglobin decreased   1/26 (3.85%)  2/24 (8.33%) 
Myelodysplasia   1/26 (3.85%)  0/24 (0.00%) 
Cardiac disorders     
Cardiac disorder   1/26 (3.85%)  0/24 (0.00%) 
Cardiac Valve Disease   0/26 (0.00%)  1/24 (4.17%) 
Chest pain   1/26 (3.85%)  1/24 (4.17%) 
Myocardial ischemia   1/26 (3.85%)  1/24 (4.17%) 
Gastrointestinal disorders     
Colitis   0/26 (0.00%)  1/24 (4.17%) 
Diarrhea   0/26 (0.00%)  1/24 (4.17%) 
Visceral arterial ischemia   0/26 (0.00%)  1/24 (4.17%) 
General disorders     
Pain   1/26 (3.85%)  0/24 (0.00%) 
Flu-like symptoms   0/26 (0.00%)  1/24 (4.17%) 
Mental Status   0/26 (0.00%)  1/24 (4.17%) 
Hepatobiliary disorders     
Cholecystitis   1/26 (3.85%)  1/24 (4.17%) 
Infections and infestations     
Catheter related infection   1/26 (3.85%)  1/24 (4.17%) 
Infection   1/26 (3.85%)  6/24 (25.00%) 
Pneumonia   1/26 (3.85%)  4/24 (16.67%) 
Skin infection   0/26 (0.00%)  1/24 (4.17%) 
Investigations     
Neutrophil count decreased   3/26 (11.54%)  1/24 (4.17%) 
INR increased   0/26 (0.00%)  1/24 (4.17%) 
Metabolism and nutrition disorders     
Blood Glucose Increase   1/26 (3.85%)  1/24 (4.17%) 
Serum sodium decrease   1/26 (3.85%)  0/24 (0.00%) 
Dehydration   0/26 (0.00%)  1/24 (4.17%) 
Musculoskeletal and connective tissue disorders     
Arthritis   1/26 (3.85%)  1/24 (4.17%) 
Back Pain   2/26 (7.69%)  1/24 (4.17%) 
Osteonecrosis   1/26 (3.85%)  0/24 (0.00%) 
Soft tissue necrosis lower limb   1/26 (3.85%)  0/24 (0.00%) 
Joint pain   0/26 (0.00%)  1/24 (4.17%) 
Muscle weakness   0/26 (0.00%)  1/24 (4.17%) 
Muscle weakness lower limb   0/26 (0.00%)  1/24 (4.17%) 
Myalgia   0/26 (0.00%)  1/24 (4.17%) 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)     
Treatment related secondary malignancy   5/26 (19.23%)  6/24 (25.00%) 
Nervous system disorders     
Syncope   1/26 (3.85%)  1/24 (4.17%) 
Psychiatric disorders     
Confusion   0/26 (0.00%)  1/24 (4.17%) 
Renal and urinary disorders     
Renal failure   0/26 (0.00%)  1/24 (4.17%) 
Respiratory, thoracic and mediastinal disorders     
Cough   1/26 (3.85%)  0/24 (0.00%) 
Pneumonitis   1/26 (3.85%)  1/24 (4.17%) 
Respiratory disorder   1/26 (3.85%)  1/24 (4.17%) 
Bronchospasm   0/26 (0.00%)  1/24 (4.17%) 
Dyspnea   0/26 (0.00%)  1/24 (4.17%) 
Skin and subcutaneous tissue disorders     
Decubitus ulcer   1/26 (3.85%)  0/24 (0.00%) 
Rash desquamating   1/26 (3.85%)  0/24 (0.00%) 
Skin disorder   0/26 (0.00%)  1/24 (4.17%) 
Vascular disorders     
Peripheral ischemia   1/26 (3.85%)  0/24 (0.00%) 
Thrombosis   2/26 (7.69%)  2/24 (8.33%) 
Indicates events were collected by systematic assessment
Show Other (Not Including Serious) Adverse Events Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 5%
Continue Lenalidomide and Dexamethasone Stem Cell Transplant x 1 or x 2
Affected / at Risk (%) Affected / at Risk (%)
Total   26/26 (100.00%)   24/24 (100.00%) 
Blood and lymphatic system disorders     
Anemia   20/26 (76.92%)  19/24 (79.17%) 
Febrile Neuropenia   0/26 (0.00%)  2/24 (8.33%) 
Eye disorders     
Blurred Vision   0/26 (0.00%)  2/24 (8.33%) 
Gastrointestinal disorders     
Constipation   3/26 (11.54%)  2/24 (8.33%) 
Diarrhea   3/26 (11.54%)  4/24 (16.67%) 
General disorders     
Edema: limb   2/26 (7.69%)  0/24 (0.00%) 
Fatigue   9/26 (34.62%)  10/24 (41.67%) 
Pain, Other   8/26 (30.77%)  6/24 (25.00%) 
Fever   0/26 (0.00%)  4/24 (16.67%) 
Infections and infestations     
Infection, other   1/26 (3.85%)  5/24 (20.83%) 
Investigations     
ALT   3/26 (11.54%)  9/24 (37.50%) 
AST   3/26 (11.54%)  5/24 (20.83%) 
Alkaline Phosphatase   1/26 (3.85%)  3/24 (12.50%) 
Bilirubin   3/26 (11.54%)  3/24 (12.50%) 
CPK   3/26 (11.54%)  1/24 (4.17%) 
Creatinine   4/26 (15.38%)  1/24 (4.17%) 
INR   4/26 (15.38%)  3/24 (12.50%) 
White Blood Cell   23/26 (88.46%)  22/24 (91.67%) 
Lymphopenia   23/26 (88.46%)  22/24 (91.67%) 
Neutrophils/Granulocytes   24/26 (92.31%)  21/24 (87.50%) 
Platelets   17/26 (65.38%)  21/24 (87.50%) 
Metabolism and nutrition disorders     
Hyperglycemia   17/26 (65.38%)  13/24 (54.17%) 
Hypoglycemia   2/26 (7.69%)  1/24 (4.17%) 
Magnesium   3/26 (11.54%)  0/24 (0.00%) 
Hypophosphatemia   15/26 (57.69%)  17/24 (70.83%) 
Hyperkalemia   5/26 (19.23%)  2/24 (8.33%) 
Hypokalemia   1/26 (3.85%)  7/24 (29.17%) 
Hyponatremia   4/26 (15.38%)  3/24 (12.50%) 
Hypoalbuminemia   0/26 (0.00%)  6/24 (25.00%) 
Musculoskeletal and connective tissue disorders     
Pain - Joint   3/26 (11.54%)  2/24 (8.33%) 
Nervous system disorders     
Neuropathy: Sensory   4/26 (15.38%)  4/24 (16.67%) 
Headache   2/26 (7.69%)  0/24 (0.00%) 
Reproductive system and breast disorders     
Pain - Pelvis   0/26 (0.00%)  2/24 (8.33%) 
Respiratory, thoracic and mediastinal disorders     
Dyspnea   0/26 (0.00%)  3/24 (12.50%) 
Skin and subcutaneous tissue disorders     
Rash Desquamation   2/26 (7.69%)  0/24 (0.00%) 
Pruritus   0/26 (0.00%)  2/24 (8.33%) 
Indicates events were collected by systematic assessment
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
Results Point of Contact
Layout table for Results Point of Contact information
Name/Title: Dr. Hani Hassoun, MD
Organization: Memorial Sloan Kettering Cancer Center
Phone: 212-639-3228
EMail: hassounh@mskcc.org
Layout table for additonal information
Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00807599     History of Changes
Other Study ID Numbers: 08-121
First Submitted: December 11, 2008
First Posted: December 12, 2008
Results First Submitted: February 15, 2019
Results First Posted: March 15, 2019
Last Update Posted: March 15, 2019